CN1401338A - Buccal tablet with pharynx purging and intestine lubricating action - Google Patents
Buccal tablet with pharynx purging and intestine lubricating action Download PDFInfo
- Publication number
- CN1401338A CN1401338A CN 01124107 CN01124107A CN1401338A CN 1401338 A CN1401338 A CN 1401338A CN 01124107 CN01124107 CN 01124107 CN 01124107 A CN01124107 A CN 01124107A CN 1401338 A CN1401338 A CN 1401338A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight
- buccal tablet
- pharynx
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A buccal lozenge for moistening throat and intestine is prepared from bugleweed, platycodon root, mulberry leaf and chrysanthemum flower.
Description
Technical field
The present invention relates to a kind of nutrient and healthcare products, particularly relate to a kind of buccal tablet with pharynx purging and intestine lubricating action.
Background technology
At present, the buccal tablet kind of producing both at home and abroad is a lot.But be confined to mostly wet one's whistle and local antiinflammation.Still rare from cleaning throat and moistening larynx to regulating the buccal tablet that the gastrointestinal microecological balance is taken into account simultaneously in the human body body.A large amount of studies show that oligosaccharide such as stachyose, Raffinose have crucial value to human body, is the growth promoting substance of bacillus bifidus useful in the human body intestinal canal.Contain oligosaccharide such as a large amount of stachyose and Raffinose among the Herba Lycopi, can promote the breeding of bacillus bifidus in the intestinal, promote enterogastric peristalsis, the loosening bowel to relieve constipation dual function.Flos Chrysanthemi, Radix Platycodonis, Folium Mori, Herba Menthae, the effect that lung heat clearing, sore-throat relieving are arranged again, eliminate the phlegm, antiinflammatory wets one's whistle.
Technology contents
The object of the invention is to provide a kind of buccal tablet with pharynx purging and intestine lubricating action.
The present invention is achieved through the following technical solutions.
1. choose crude drug: Herba Lycopi 200-800 weight portion Radix Platycodonis 100-400 weight portion,
Folium Mori 100-400 weight portion Flos Chrysanthemi 100-400 weight portion
2. preparation technology: with 10-20 times of temperature is hot water extraction above-mentioned raw materials 30-60 minute more than 80 ℃, with the screen filtration of extracting solution by more than 60 orders, collect its filtrate, the reuse squeezer squeezes filtering residue, squeeze the juice and mix, use filter press or rotary drum filter to carry out fine straining then with filtrate.The soluble solid of gained filtrate is 3-10%.
3. filtrate concentrates with the vacuum and low temperature concentrator.Vacuum is-0.05-0.08MPa that temperature is 40-60 ℃.If when being spray dried to powder, the concentration multiple is 5-10 times; If when adopting a spray drying grain or waving the granulation machine pelletize, cycles of concentration is more than 10 times.
4. with medicine concentrated solution spray drying, drug level is controlled at 30-50% and is advisable.For reducing the viscosity of drug solution, can in concentrated solution, add white sugar or the maltodextrin of 5-20% (weight).The inlet temperature of spraying is 130-160 ℃, and outlet temperature is 60-80 ℃, and product moisture content is below 5%.Also can adopt a sponging granulator pelletize, be carrier with Icing Sugar or maltodextrin, carries out mist projection granulating, sieves with vibrosieve then.
5. drug powder is mixed with other adjuvants: take by weighing drug powder 50-100 weight portion, stachyose 10-30 weight portion, acidic flavoring agent 0.1-0.5 weight portion, sweetener 1-3 weight portion, vitamin C 0.1-0.5 weight portion, fumet 0.05-0.1 weight portion, Mentholum 0.1-1.0 weight portion, tabletting behind the mix homogeneously, every heavy 0.5-0.6 gram.Day clothes 3-6 sheet.
2. the proportioning of buccal tablet crude drug of the present invention can be Herba Lycopi's 600 weight portions, Radix Platycodonis 200 weight portions, Folium Mori 200 weight portions, Flos Chrysanthemi 200 weight portions.
Medicament composing prescription of the present invention is reasonable, and the effect equilibrium has good pharynx purging and intestine lubricating action, is a kind of health care medicine that most of people take that is suitable for.The human experiment visual report of buccal tablet cleaning throat and moistening larynx of the present invention is as follows: 1. method 1.1 study subjects: select the age at 18 years old to 65 years old, the chronic pharyngitis patient of main organs illness such as no severe cardiac, liver, kidney is a study subject, totally 46 examples adopt the own control design.1.2 the experimenter includes standard in: the 1.2.1 medical history: subjective symptom has pharyngalgia, itching throat, dry pharynx, dry cough, foreign body sensation polylogia to increase the weight of etc.1.2.2 check: pharyngeal mucosa edema, mucous hyperemia, retropharyneal folliculosis, (classification: 3 grades of severes, 2 grades of moderates, slight 1 grade), secretions adhere to.
Have above-mentioned symptom and check more than 1 or 1 that finding can include observation in.1.2.3 exclusion standard: 1.2.3.1 has confirmed person due to some invisible pathological changes of oropharynx, nasopharynx, throat, nose, larynx, esophagus, cervical region and whole body on inspection.1.2.3.2 the age, gestation or women breast-feeding their children reached this product allergy sufferers under-18s or over-65s person.1.2.3.3 merge to have the inclination, serious primary disease and psychotics such as cerebrovascular, liver, kidney and hemopoietic system.1.2.3.4 do not meet the standard of including in, buccal is not tried the experimenter of thing in accordance with regulations, data not umbra is rung curative effect or safety judgement person.1.3 instructions of taking:
Every order 3 times, each 2 1.4 instruments and reagent: U.S. Ku Erte GT type blood counting instrument, FDAC 170 automatic biochemistry analyzers, the biochemical reagents box is all provided by middle living company.2. observation index:
Every index when experiment begins and finish each test once, and check pharyngeal, inquiry semiography situation of change.2.1 effect observation 2.1.1 observation of symptoms: detailed medical history-taking, observe cardinal symptom: pharyngalgia, itching throat, dry pharynx, dry cough, foreign body sensation polylogia increase the weight of etc., by symptom weight (slight, moderate, severe) analytic statistics doing well,improving rate.2.1.2 pharyngeal inspection: signs such as pharyngeal mucosa edema, mucous hyperemia, retropharyneal folliculosis, secretions, by light, in, heavily be divided into I, II, III level, take the before and after look sign and change, calculate its improvement rate.2.1.3 throat swab is cultivated: blood meida was cultivated after 24 hours, and direct smear is done Gram, carries out biochemical reaction and signing again.2.1.4 blood routine is checked the mensuration that the 2.2.1 biochemical indicator is observed in red blood cell count(RBC), hemoglobin, numeration of leukocyte 2.2 safeties
T-CHOL, triglyceride, blood glucose, glutamate pyruvate transaminase, inosine, blood urea nitrogen, total bilirubin.2.2.2 Abdominal B type ultrasonography, electrocardiogram, the fluoroscopy of chest of X line.3. effect criterion is formulated with reference to " the new Chinese medicine clinical research guideline " of Ministry of Public Health issue.3.1 produce effects: sx or disappearance, pharyngeal sign alleviate 2 grades, and throat swab is cultivated and turned out cloudy.3.2 effectively: sx, pharyngeal sign alleviates the 1-2 level.3.3 it is invalid: symptom, the equal no change of sign.4. result: 4.1 physical data: observe 46 routine experimenters altogether, male's 11 examples wherein, women's 35 examples, minimum 22 years old of age, maximum 55 years old, average 43 ± 7 years old.The course of disease is the shortest 2 years, and is the longest 30 years, average 12 ± 6 years.4.2 cleaning throat and moistening larynx effect:
The cleaning throat and moistening larynx effect example digital display of table 1 buccal tablet of the present invention is imitated the enabledisable total effective rate
Number % number % number % number %46 5 10.9 33 71.7 8 17.4 38 82.64.3 doing well,improving situations:
Table 2. cardinal symptom improvement situation symptom example digital display effect enabledisable improvement rate % pharyngalgia 35 6 24 5 85.7 is swallowed 40 9 25 6 85.0 dry throats, 45 2 31 12 73.3 dry cough, 32 2 18 12 62.5 foreign body sensations, 40 3 23 14 65.04.4 that itch and is improved situation because of section's sign:
The pharyngeal sign of table 3. is improved the pharyngeal sign example of situation digital display effect enabledisable improvement rate mucous hyperemia 41 6 28 7 82.9 myxedemas 36 5 25 6 83.3 pharynx rear wall lymph foilicie hyperplasias 35 4 22 9 72.2 secretion and is adhered to the cultivation of 27 5 19 3 81.54.5 throat swabs and routine blood test situation of change:
Throat swab was cultivated the positive routine number negative conversion rate % of variation project before and after table 4 was on probation
The extracorporeal bacteria inhibitor test of alpha streptococcus 51 80.0 Klebsiella Pneumoniae 92 77.8 hemophilus influenzas, 18 5 72.24.6 buccal tablet of the present invention after the test-meal before the test-meal
Lung streptococcus, hemophilus influenza there is bacteriostasis.4.7 blood biochemistry checking situation before and after the buccal tablet test-meal of the present invention
(the numeration of leukocyte (* 10 after the test-meal before the project test-meal of X ± SD) of blood biochemistry checking situation before and after table 5 test-meal
9/ L) 5.4 ± 1.3 5.6 ± 1.4 red blood cell count(RBC) (* 10
12/ L) before and after 4.5 ± 0.5 4.7 ± 2.1 hemoglobin (g/L) 143.2.0 ± 14.7 142.7 ± 15.2 glutamic-pyruvic transaminase (U/L), 16.9 ± 7.5 17.8 ± 2.5 total bilirubins (mg/dl), 0.6 ± 0.2 0.6 ± 0.4 creatinine (mg/dl), 0.9 ± 0.4 1.1 ± 0.5 urea nitrogen (mg/dl), 10.4 ± 3.7 9.8 ± 4.2 fasting blood-glucoses (mg/dl), 83.9 ± 9.5 85.1 ± 8.4 T-CHOLs (mg/dl), 130.8 ± 35.9 132.4 ± 37.5 triglycerides (mg/dl), 84.2 ± 39.7 82.1 ± 34.5 test-meals every blood parameters all in range of normal value. 5. sum up:
Buccal tablet of the present invention has tangible cleaning throat and moistening larynx effect.Buccal tablet of the present invention has certain bacteriostasis.Buccal tablet of the present invention is to main physical signs effects of having clear improvement such as cardinal symptoms such as pharyngeal pharyngalgia, itching throat, dry pharynx, foreign body sensation and mucous hyperemia, myxedema, retropharyneal folliculosis, and total effective rate is 82.6%.Buccal tablet of the present invention is not observed any discomfort and untoward reaction during human experiment.
Function of relaxing bowel test report 1. methods 1.1 laboratory animals of buccal tablet of the present invention: select the healthy Kunming female mice (approval number is moved word SCK11-00-0006 number for the doctor) of zooscopy institute of Chinese Academy of Medical Sciences breeding farm breeding for use, body weight 18-22g.1.2 dosage is selected: buccal tablet human body recommended amounts of the present invention is 6 of everyone (adult) every days.The dose,equivalent of mice is equivalent to 10 times of human body recommended amounts, i.e. 2.0g/kg (middle dosage) upper and lowerly respectively establishes a dosage group: 3.0g/kg body weight (high dose) and 1.0g/kg body weight (low dosage).The continuous irrigation stomach was surveyed index after 14 days.1.3 instrument and reagent: operating scissors, ophthalmology tweezer, ruler, syringe, balance, activated carbon powder, Radix Acaciae senegalis, compound diphenoxylate.1.4 experimental technique: the test of 1.4.1 intestinal propulsion is divided into blank group, model control group, low dose group, middle dosage group, high dose group with laboratory animal, every group of 15 mices.Each test group is tried thing by the 0.2mL/10gb.w per os, and matched group gives clean water, once a day, and continuous 14 days.Each treated animal fasting 24 hours (freely drinking water therebetween) before the test, before on-test, test group and matched group are tried thing and clean water respectively once again, after 30 minutes, model control group and three dosage groups give compound diphenoxylate (0.2mL/10gb.w), and the blank group gives clean water.After 30 minutes, give respectively to organize mice prepared Chinese ink (containing 5% activated carbon powder, 10% Radix Acaciae senegalis) again, give prepared Chinese ink and take off cervical vertebra execution animal after 20 minutes, open the abdominal cavity and separate mesentery, the clip upper end is the intestinal tube to ileocecus from pylorus, lower end, places on the pallet, gently small intestinal is pulled into straight line, measuring intestinal tube length is " small intestinal total length ", is " prepared Chinese ink propelling length " from pylorus to prepared Chinese ink forward position, calculates prepared Chinese ink propelling rate:
1.4.2 defecation time, the mensuration animal of stool and feces volume is divided into the blank group, the constipation model control group, low dose group, middle dosage group and high dose group, every group 10, low, in, high dose group was tried thing 14 days continuously, each treated animal fasting 24 hours (freely drinking water therebetween) before the experiment, constipation model group and three dosage groups are irritated stomach and are given compound diphenoxylate 50mg/kg (0.2ml/10g), give behind the compound diphenoxylate 1 hour, low, in, high dose group is given at last and is once tried thing, 5 treated animals are all raised separately, normal drinking-water feed, every animal of observed and recorded is the defecation required time first, 12 hours defecation grain numbers and weight.1.5 experimental data is added up with variance analysis.2. result's 2.1 buccal tablets of the present invention see Table 6 to the influence of mice ahead running:
Table 6 buccal tablet of the present invention is to dosage group 15 63.0 ± 3.6** high dose group 15 69.2 ± 5.2** among group number of animals (only) the prepared Chinese ink propelling rate (100%) that influences blank 15 68.1 ± 5.8 model control group 15 42.4 ± 4.1## low dose group 15 53.0 ± 4.6* of mouse small intestine ahead running
* P＜0.05 * * P＜0.01 is with blank group ratio
##P＜0.01 is with the model control group ratio
By table 6 as seen, compound diphenoxylate model control group intestinal propulsion rate is starkly lower than blank group (P＜0.01), per os gave the pharynx purging and intestine lubricating buccal tablet of mice various dose after 14 days, the prepared Chinese ink propelling rate of low dose group, middle dosage group, high dose group mice illustrates that apparently higher than the intestinal propulsion rate (P＜0.05, P＜0.01) of compound diphenoxylate model control group buccal tablet of the present invention has the improvement effect to the intestinal propulsion reduction that compound diphenoxylate causes.2.2 buccal tablet of the present invention sees Table 7 to the influence of mice stool and feces volume:
Table 7 lozenge of the present invention affects first defecation time of group to mouse defecation rate and feces volume, (minute) the fecal grains stool weight, (gram) blank 136.1 ± 22.3 66.7 ± 10.4 0.70 ± 0.09 Constipation Models contrast 261.7 ± 70.6 ◇ 31.3 ± 12.4 ◇ 0.32 ± 0.14 ◇ low dose group 190.1 ± 72.5 32.8 ± 15.9 0.34 ± 0.17 low dose group 164.2 ± 49.7** 37.9 ± 10.1*, 0.44 ± 0.14* low dose group, 120.0 ± 35.2**, 42.7 ± 11.2**, 0.50 ± 0.16**
*: compare P＜0.05 with the constipation model
*: compare P＜0.01 with the constipation model
◇: relatively by table 7 as seen give compound diphenoxylate and make the establishment of mice constipation model in P＜0.01 with blank; Per os gives mice buccal tablet of the present invention 14 days, and hundred Australia of middle and high dosage tie up the defecation time first that he can obviously shorten mice with constipation, increases the defecation grain number and the defecation weight of mice with constipation.3. conclusion
Per os gives the buccal tablet of the present invention 14 days of mice various dose, can obviously strengthen the intestinal propulsion motion of mice, shortens the defecation time first of mice with constipation, increases the defecation grain number and the defecation weight of mice with constipation.As seen by inferior, buccal tablet of the present invention has the effect of loosening bowel to relieve constipation.
Embodiment:
Take by weighing Herba Lycopi's 300 grams, Flos Chrysanthemi 100 grams, Radix Platycodonis 100 grams, Folium Mori 100 grams add 10 liters in water after the cleaning, and heated and boiled, is filtered with 60 mesh sieves after 30 minutes in 80 ℃ of extractions, collects filtrate.Filtering residue mixes with filtrate through the squeezing extracting juice again, gets 7.6 liters of extracting solution.Then, filter through diatomite filter, get about 7.0 liters of transparent liquid, soluble solid content is 5%.Vacuum concentration, vacuum be-0.08Mpa, is concentrated into 1.2 liters, and soluble solid is 32%.In concentrated solution, add white sugar and maltodextrin each 50 the gram, heating for dissolving and stir after, carry out spray drying, collect its dried powder totally 350 the gram.Take by weighing drug powder 50 grams, stachyose 20 grams, acidic flavoring agent 0.3 gram, sweetener 2 grams, vitamin C 0.3 gram, fumet 0.1 gram, Mentholum 0.6 gram, tabletting behind the mix homogeneously, every heavy 0.5-0.6 gram.
Claims (4)
1, a kind of buccal tablet with pharynx purging and intestine lubricating action is characterized in that these health product make with following raw material medicaments:
Herba Lycopi 200-800 weight portion Radix Platycodonis 100-400 weight portion,
Folium Mori 100-400 weight portion Flos Chrysanthemi 100-400 weight portion.
2, the buccal tablet with pharynx purging and intestine lubricating action as claimed in claim 1 is characterized in that these health product make with following raw material medicaments:
Herba Lycopi's 600 weight portion Radix Platycodoniss 200 weight portions,
Folium Mori 200 weight portion Flos Chrysanthemis 200 weight portions.
3, a kind of preparation method with buccal tablet of pharynx purging and intestine lubricating action is characterized in that this method is:
Herba Lycopi 200-800 weight portion Radix Platycodonis 100-400 weight portion,
Folium Mori 100-400 weight portion Flos Chrysanthemi 100-400 weight portion preparation technology: with 10-20 times of temperature is hot water extraction above-mentioned raw materials 30-60 minute more than 80 ℃, with the screen filtration of extracting solution by more than 60 orders, collect its filtrate, the reuse squeezer squeezes filtering residue, squeeze the juice and mix, use filter press or rotary drum filter to carry out fine straining then with filtrate; The soluble solid of gained filtrate is 3-10%; Filtrate concentrates with the vacuum and low temperature concentrator; Vacuum is-0.05-0.08MPa that temperature is 40-60 ℃; Be spray dried to powder, the concentration multiple is 5-10 times; Drug level is controlled at 30-50% and is advisable; For reducing the viscosity of drug solution, can in concentrated solution, add white sugar or the maltodextrin of 5-20% (weight); The inlet temperature of spraying is 130-160 ℃, and outlet temperature is 60-80 ℃, and product moisture content is below 5%; Also can adopt a sponging granulator pelletize, be carrier with Icing Sugar or maltodextrin, carries out mist projection granulating, sieves with vibrosieve then; Drug powder is mixed with other adjuvants: take by weighing drug powder 50-100 weight portion, stachyose 10-30 weight portion, acidic flavoring agent 0.1-0.5 weight portion, sweetener 1-3 weight portion, vitamin C 0.1-0.5 weight portion, fumet 0.05-0.1 weight portion, Mentholum 0.1-1.0 weight portion, tabletting behind the mix homogeneously.
4, a kind of preparation method with buccal tablet of pharynx purging and intestine lubricating action, it is characterized in that this method is: take by weighing Herba Lycopi's 300 weight portions, Flos Chrysanthemi 100 weight portions, Radix Platycodonis 100 weight portions, Folium Mori 100 weight portions, add 10 times in water after the cleaning, heated and boiled,, filter after 30 minutes in 80 ℃ of extractions, collect filtrate with 60 mesh sieves; Filtering residue mixes with filtrate through the squeezing extracting juice again, filters through diatomite filter, and soluble solid content is 5%; Vacuum concentration, vacuum be-0.08Mpa, is concentrated into the 15-20% of former filtered solution, and soluble solid is 32%; In concentrated solution, add each 50 weight portion of white sugar and maltodextrin, heating for dissolving and stir after, carry out spray drying, collect its dried powder totally 350 weight portions; Take by weighing drug powder 50 weight portions, stachyose 20 weight portions, acidic flavoring agent 0.3 weight portion, sweetener 2 weight portions, vitamin C 0.3 weight portion, fumet 0.1 weight portion, Mentholum 0.6 weight portion, tabletting behind the mix homogeneously, every heavy 0.5-0.6 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011241071A CN1168461C (en) | 2001-08-13 | 2001-08-13 | Buccal tablet with pharynx purging and intestine lubricating action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011241071A CN1168461C (en) | 2001-08-13 | 2001-08-13 | Buccal tablet with pharynx purging and intestine lubricating action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1401338A true CN1401338A (en) | 2003-03-12 |
| CN1168461C CN1168461C (en) | 2004-09-29 |
Family
ID=4665506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011241071A Expired - Fee Related CN1168461C (en) | 2001-08-13 | 2001-08-13 | Buccal tablet with pharynx purging and intestine lubricating action |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1168461C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793736A (en) * | 2012-07-25 | 2012-11-28 | 青岛文创科技有限公司 | Buccal tablet with removing throat heat and promoting diuresis |
| CN103859376A (en) * | 2012-12-10 | 2014-06-18 | 天津红日药业股份有限公司 | Formula and preparation method of life cultivation and health preservation food helpful for clearing throat heat and soothing throat |
-
2001
- 2001-08-13 CN CNB011241071A patent/CN1168461C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793736A (en) * | 2012-07-25 | 2012-11-28 | 青岛文创科技有限公司 | Buccal tablet with removing throat heat and promoting diuresis |
| CN103859376A (en) * | 2012-12-10 | 2014-06-18 | 天津红日药业股份有限公司 | Formula and preparation method of life cultivation and health preservation food helpful for clearing throat heat and soothing throat |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1168461C (en) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899543A (en) | External plaster for treating child fever and preparing method | |
| CN101062234A (en) | Chinese medicine for treating constipation for children | |
| CN100571752C (en) | The compound Chinese medicinal preparation of treatment rhinitis | |
| CN101904489A (en) | Preparation method and application of phylloporia ribis ryvarden series preparations | |
| CN105031197B (en) | A kind of Chinese medicine composition and the preparation method and application thereof with throat soothing function of moistening and cleaning throat | |
| CN102319294A (en) | Double-vanilla preparation and preparation method thereof | |
| CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
| CN101564517B (en) | Traditional Chinese medicine for treating children cough and asthma and preparation thereof | |
| CN101757083B (en) | Costunolide-containing traditional Chinese medicine composition for treating gastrointestinal diseases and preparation method thereof | |
| CN101366860B (en) | Jiaomei oral liquid for benefiting sleep and removing speckle | |
| CN106310017B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi deficiency syndrome | |
| CN1401338A (en) | Buccal tablet with pharynx purging and intestine lubricating action | |
| CN103735663B (en) | Traditional Chinese medicine for reducing blood glucose and preparation method thereof | |
| CN1150927C (en) | Stomatopathy and throat disease treating health care medicine and its production process | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN100372555C (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN101485730A (en) | Medicament composition for treating children's exogenous fever and preparation method thereof | |
| CN1429578A (en) | Medicinal atomization liquid for treating pharyngitis and its manufacturing process | |
| CN101337016A (en) | Medicine for treating postnasal catarrh and its preparation method | |
| CN1579467A (en) | Anti-virus medicine | |
| CN1686211A (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN101773620B (en) | Heat-clearing stranguria-treating drug | |
| CN1163116A (en) | Compound health medicinal emblic tablet and its producing technology | |
| CN106581520B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung qi deficiency syndrome | |
| CN1555849A (en) | Intestine moistening oral liquid and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |